Janssen has initiated a first-of-its-kind, large-scale trial of its plaque psoriasis monoclonal antibody Tremfya (guselkumab) that will only enroll minority participants.

The phase 3b multicenter trial will assess the safety and efficacy of Tremfya in patients who identify as non-White and aims to enroll around 200 U.S. and Canadian patients with moderate-to-severe plaque psoriasis and/or moderate-to-severe scalp psoriasis. Participants will be monitored for approximately two years.

The trial will deliver additional data and information on psoriatic disease burden and the patient journey in Black, Hispanic, Asian and Native American patients, and other minorities. Although Tremfya’s safety and efficacy profile is well-established across an extensive adult population, there’s still a need for further information on its safety and efficacy in minorities. According to Janssen, the majority of phase 3 psoriasis trials across topical, oral and biologic drugs (86 percent) have enrolled mostly White patients.